lapatinib has been researched along with Bilirubinemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Briley, LP; Cox, CJ; Dilthey, A; Iqbal, Z; King, KS; Li, L; McVean, G; Nelson, MR; Newcombe, PJ; Parham, LR; Shen, J; Slater, AJ; Spraggs, CF | 1 |
| Burns, K; Chau, N; Kichenadasse, G; Knights, KM; Mackenzie, PI; McKinnon, RA; Miners, JO; Rowland, A; Tucker, GT | 1 |
1 trial(s) available for lapatinib and Bilirubinemia
| Article | Year |
|---|---|
Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01.
Topics: Alanine Transaminase; Alleles; Antineoplastic Agents; Breast Neoplasms; Case-Control Studies; Chemical and Drug Induced Liver Injury; ErbB Receptors; Female; Genome-Wide Association Study; HLA-DRB1 Chains; Humans; Hyperbilirubinemia; INDEL Mutation; Lapatinib; Polymorphism, Single Nucleotide; Quinazolines; Risk | 2016 |
1 other study(ies) available for lapatinib and Bilirubinemia
| Article | Year |
|---|---|
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
Topics: Bilirubin; Catalysis; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Kinetics; Lapatinib; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Sulfonamides | 2017 |